XSpray Pharma AB (XSPRAY) - Total Assets
Based on the latest financial reports, XSpray Pharma AB (XSPRAY) holds total assets worth Skr736.39 Million SEK (≈ $79.25 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore XSpray Pharma AB (XSPRAY) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
XSpray Pharma AB - Total Assets Trend (2015–2025)
This chart illustrates how XSpray Pharma AB's total assets have evolved over time, based on quarterly financial data. See XSPRAY book value for net asset value and shareholders' equity analysis.
XSpray Pharma AB - Asset Composition Analysis
Current Asset Composition (December 2025)
XSpray Pharma AB's total assets of Skr736.39 Million consist of 23.8% current assets and 76.2% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 20.0% |
| Accounts Receivable | Skr3.84 Million | 0.5% |
| Inventory | Skr22.30 Million | 2.9% |
| Property, Plant & Equipment | Skr70.99 Million | 9.2% |
| Intangible Assets | Skr512.19 Million | 66.6% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how XSpray Pharma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see XSPRAY market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: XSpray Pharma AB's current assets represent 23.8% of total assets in 2025, a decrease from 88.9% in 2015.
- Cash Position: Cash and equivalents constituted 20.0% of total assets in 2025, down from 79.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 66.0% of total assets, an increase from 7.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 66.6% of total assets.
XSpray Pharma AB Competitors by Total Assets
Key competitors of XSpray Pharma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
XSpray Pharma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 1.24 | 13.60 |
| Quick Ratio | 0.87 | 1.01 | 13.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr3.27 Million | Skr31.25 Million | Skr237.44 Million |
XSpray Pharma AB - Advanced Valuation Insights
This section examines the relationship between XSpray Pharma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.99 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | -3.4% |
| Total Assets | Skr769.35 Million |
| Market Capitalization | $86.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values XSpray Pharma AB's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: XSpray Pharma AB's assets decreased by 3.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for XSpray Pharma AB (2015–2025)
The table below shows the annual total assets of XSpray Pharma AB from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr769.35 Million ≈ $82.79 Million |
-3.39% |
| 2024-12-31 | Skr796.34 Million ≈ $85.70 Million |
+4.06% |
| 2023-12-31 | Skr765.26 Million ≈ $82.35 Million |
+30.72% |
| 2022-12-31 | Skr585.43 Million ≈ $63.00 Million |
-6.02% |
| 2021-12-31 | Skr622.90 Million ≈ $67.03 Million |
+2.91% |
| 2020-12-31 | Skr605.30 Million ≈ $65.14 Million |
+51.07% |
| 2019-12-31 | Skr400.67 Million ≈ $43.12 Million |
+28.22% |
| 2018-12-31 | Skr312.49 Million ≈ $33.63 Million |
+93.59% |
| 2017-12-31 | Skr161.41 Million ≈ $17.37 Million |
+211.24% |
| 2016-12-31 | Skr51.86 Million ≈ $5.58 Million |
+246.88% |
| 2015-12-31 | Skr14.95 Million ≈ $1.61 Million |
-- |
About XSpray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the tr… Read more